UK Government and Lilly Announce Partnership to Boost Life Sciences Innovation

The UK government and Eli Lilly and Company, a leading pharmaceutical company, today announced a strategic partnership aimed at accelerating life sciences innovation and addressing significant health challenges. The collaboration will involve a £279 million investment in the UK life sciences sector.

A key component of the partnership is the planned launch of the first “Lilly Gateway Labs” innovation accelerator in Europe. This facility will provide early-stage life sciences businesses with lab space, mentorship, and potential financial backing, supporting their development of transformative medicines.

The UK government and Lilly also intend to collaborate on research and development related to obesity, a major public health issue. The partnership will focus on developing innovative approaches to treating obesity and improving long-term health outcomes for those affected.

The partnership is expected to create new jobs in the UK life sciences sector, contribute to the UK’s economic growth and competitiveness, and have a significant impact on the UK’s healthcare system.

Health and Social Care Secretary Wes Streeting expressed enthusiasm for the partnership, stating that it will help the UK become a world leader in life sciences and bring life-changing treatments closer to NHS patients.

David A. Ricks, Chair and CEO of Eli Lilly and Company, expressed the company’s commitment to improving health for people living with obesity and highlighted the significance of the partnership in accelerating innovation and advancing care delivery models

The UK government has a long-standing commitment to supporting the life sciences sector and innovation, and Lilly is a global pharmaceutical company with a strong track record of research and development.

The partnership is expected to have a significant impact on the UK’s healthcare system and economy.